中银国际发布研报称药明康德(02359.HK)上半年业绩表现强劲收入及净利润增长稳健利润率扩张TIDES业务表现突出同时

智通财经
Aug 04
中银国际发布研报称药明康德(02359.HK)上半年业绩表现强劲收入及净利润增长稳健利润率扩张TIDES业务表现突出同时化学业务韧性增长有助抵销临床CRO及测试业务的疲软。管理层上调2025年收入指引至425亿至435亿元人民币即持续经营业务料增长13%至17%资本开支维持70亿至80亿元人民币不变。 中银国际将药明康德今明两年盈利预测上调15%及22%目标价从81港元升至122港元维持“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10